Player FM - Internet Radio Done Right
0-10 subscribers
Checked 4d ago
تمت الإضافة منذ قبل three أعوام
المحتوى المقدم من NeurologyLive® Mind Moments®. يتم تحميل جميع محتويات البودكاست بما في ذلك الحلقات والرسومات وأوصاف البودكاست وتقديمها مباشرة بواسطة NeurologyLive® Mind Moments® أو شريك منصة البودكاست الخاص بهم. إذا كنت تعتقد أن شخصًا ما يستخدم عملك المحمي بحقوق الطبع والنشر دون إذنك، فيمكنك اتباع العملية الموضحة هنا https://ar.player.fm/legal.
Player FM - تطبيق بودكاست
انتقل إلى وضع عدم الاتصال باستخدام تطبيق Player FM !
انتقل إلى وضع عدم الاتصال باستخدام تطبيق Player FM !
NeurologyLive® Mind Moments®
وسم كل الحلقات كغير/(كـ)مشغلة
Manage series 3340456
المحتوى المقدم من NeurologyLive® Mind Moments®. يتم تحميل جميع محتويات البودكاست بما في ذلك الحلقات والرسومات وأوصاف البودكاست وتقديمها مباشرة بواسطة NeurologyLive® Mind Moments® أو شريك منصة البودكاست الخاص بهم. إذا كنت تعتقد أن شخصًا ما يستخدم عملك المحمي بحقوق الطبع والنشر دون إذنك، فيمكنك اتباع العملية الموضحة هنا https://ar.player.fm/legal.
Mind Moments®, a podcast from NeurologyLive® (https://www.neurologylive.com/) , brings you exclusive interviews with experts in neurologic disorders. Listen in to hear the latest clinical and research updates from major medical conferences, as well as insights on the management of complex disorders, including epilepsy, migraine, Alzheimer disease, stroke, multiple sclerosis, Parkinson disease, and more. For more expert insight into neurology, visit NeurologyLive.com (https://www.neurologylive.com/) .
…
continue reading
151 حلقات
وسم كل الحلقات كغير/(كـ)مشغلة
Manage series 3340456
المحتوى المقدم من NeurologyLive® Mind Moments®. يتم تحميل جميع محتويات البودكاست بما في ذلك الحلقات والرسومات وأوصاف البودكاست وتقديمها مباشرة بواسطة NeurologyLive® Mind Moments® أو شريك منصة البودكاست الخاص بهم. إذا كنت تعتقد أن شخصًا ما يستخدم عملك المحمي بحقوق الطبع والنشر دون إذنك، فيمكنك اتباع العملية الموضحة هنا https://ar.player.fm/legal.
Mind Moments®, a podcast from NeurologyLive® (https://www.neurologylive.com/) , brings you exclusive interviews with experts in neurologic disorders. Listen in to hear the latest clinical and research updates from major medical conferences, as well as insights on the management of complex disorders, including epilepsy, migraine, Alzheimer disease, stroke, multiple sclerosis, Parkinson disease, and more. For more expert insight into neurology, visit NeurologyLive.com (https://www.neurologylive.com/) .
…
continue reading
151 حلقات
كل الحلقات
×N
NeurologyLive® Mind Moments®

1 135: Invaluable Role of Social Support in Narcolepsy and Idiopathic Hypersomnia Care 16:22
16:22
التشغيل لاحقا
التشغيل لاحقا
قوائم
إعجاب
احب16:22
Welcome to the NeurologyLive ® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, Julie Flygare, JD, president and chief executive officer of Project Sleep, shared her personal and professional insights into the critical role of social connections for patients living with narcolepsy and idiopathic hypersomnia. Drawing from her journey with narcolepsy, Flygare highlighted the challenges of isolation at diagnosis and the transformative power of peer support and advocacy. She delved into survey findings that underscore the rarity of social connections among patients and their impact on adjustment and well-being. Additionally, Flygare offered actionable recommendations for clinicians to integrate social support into practice, emphasizing the value of patient advocacy organizations and fostering meaningful connections. Above all, her inspiring perspective shed light on the intersection of community, research, and clinical care in sleep health. Looking for more narcolepsy discussion? Check out the NeurologyLive ® Narcolepsy clinical focus page . Episode Breakdown: 1:00 – Challenges and importance of social connections 5:45 – Building a thriving community and research impact 7:30 – Insights from patient surveys on social support 10:30 – Neurology News Minute 12:25 – Recommendations for clinicians on social support The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: FDA Approves Mirdametinib for NF1-Associated Plexiform Neurofibromas in Adults and Children FDA Approves Tablet Formulation of Risdiplam for Spinal Muscular Atrophy Solid Reports Positive Data for SGT-003 Gene Therapy in Phase 1/2 Trial of Duchenne Thanks for listening to the NeurologyLive ® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com .…
N
NeurologyLive® Mind Moments®

1 134: Previewing the 2025 ACTRIMS Forum 15:37
15:37
التشغيل لاحقا
التشغيل لاحقا
قوائم
إعجاب
احب15:37
Welcome to the NeurologyLive ® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, Veronique Miron, PhD, The John David Eaton Chair in Multiple Sclerosis at the University of Toronto, gave a clinical overview of the 2025 ACTRIMS Forum, which is held February 27-March 1, in West Palm Beach, Florida. Miron, an expert in the field, spoke on the reasons behind this year's theme of "Making Connections," as well as some of the most notable and innovative sessions attending clinicians should keep their eyes on. Additionally, she spoke on how the curriculum at this year's meeting aligns with the most recent MS McDonald Diagnostic Criteria that was presented at ECTRIMS 2024. Miron also spoke on the different seminars that cover drug development, innovative new treatment approaches, and Bruton Tyrosine Kinase (BTK) inhibitors. Furthermore, she provided commentary on how this year's meeting differs from previous iterations of ACTRIMS, highlighting some of the changes to the agenda and the advances in MS research. Looking for more multiple sclerosis discussion? Check out the NeurologyLive ® Multiple sclerosis clinical focus page . Episode Breakdown: 1:10 – Reasons behind "Making Connections" theme 2:50 – Overviewing key unique sessions and forums from the meeting 5:10 – Aligning curriculum with 2024 MS McDonald Criteria 7:00 – Neurology News Minute 9:00 – Drug development topics from ACTRIMS 2025 12:20 – Differences between ACTRIMS 2025 vs ACTRIMS 2024 The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: FDA Approves Axsome Therapeutics’ AXS-07 for Migraine Treatment FDA Approves Vertex Pharmaceuticals' Suzetrigine for Acute Pain Management FDA Approves Apomorphine Infusion Device SPN-830 as New Parkinson Treatment Thanks for listening to the NeurologyLive ® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com .…
N
NeurologyLive® Mind Moments®

1 133: Clinical Guidance on Neurostimulation for Lennox-Gastaut Syndrome 25:23
25:23
التشغيل لاحقا
التشغيل لاحقا
قوائم
إعجاب
احب25:23
Welcome to the NeurologyLive ® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, epilepsy expert Depobam Samanta, MD, MS, FAAP, FAES, sat down to discuss a recently published guidance paper from members of the Pediatric Epilepsy Research Consortium that provides recommendations for neuromodulation approaches to treat Lennox-Gastaut syndrome (LGS). Samanta, medical director of the Arkansas Children's Comprehensive Epilepsy Program, gave a clinical overview of the paper, highlighting the various neuromodulatory devices and their use, and the ways to improve treatment selection and personalization. Additionally, he talked about some of the potential complications with these devices as well as initiation and titration strategies for easy initiation. Furthermore, he spoke about ways to take neuromodulation to the next level, giving insight on creative trial designs, overcoming sham-controlled studies, and the necessary research to expand these approaches. Looking for more epilepsy discussion? Check out the NeurologyLive ® Epilepsy clinical focus page . Episode Breakdown: 1:05 – Overview of the published guidance and reasons behind the paper 5:15 – Patient selection for neuromodulation and tailoring treatments by patient and preference 8:25 – Overcoming complications with neuromodulation devices 11:25 – Multidisciplinary team necessary for successful implementation of neuromodulation 13:15 – Neurology News Minute 15:15 – Initiation and titration strategies for vagus nerve stimulation, deep brain stimulation, and resective surgery 18:30 – Next steps in research and expanding neuromodulation for patients with LGS 21:10 – Finding creative trial designs to test neuromodulation devices, combination approaches The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: FDA Accepts BLA for Subcutaneous Autoinjector Formulation of Lecanemab Cell Therapy Bemdaneprocel Advances to Phases 3 Registrational Trial in Parkinson Disease Real-World Study Highlights Positive Treatment Benefits of Tofersen on ALS Disease Progression, Function Thanks for listening to the NeurologyLive ® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com .…
N
NeurologyLive® Mind Moments®

1 132: Aiding Diagnosis of Synucleinopathies Through SAAmplify-aSYN Biomarker Test 22:48
22:48
التشغيل لاحقا
التشغيل لاحقا
قوائم
إعجاب
احب22:48
Welcome to the NeurologyLive ® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, Russ Lebovitz, MD, PhD, chief executive officer and cofounder of Amprion, discussed the company's SAAmplify-aSYN biomarker test, a first-in-class qualitative laboratory developed test and the only seed amplification assay available to aid in the diagnosis of synucleinopathies such as Parkinson disease (PD) and multiple system atrophy (MSA). Lebovitz provided insight on the new technology and its remarkable accuracy in identifying underling a-synuclein pathology using fluorescence changes. He gave a complete overview of the notable study published in The Lancet Neurology that further tested and validated the assay among a heterogenous group of synucleinopathies. Furthermore, he provided clinical context on the feasibility of the assay, the potential for clinical use, and the continued validation needed. Looking for more movement disorder discussion? Check out the NeurologyLive ® Movement disorder clinical focus page . Episode Breakdown: 1:05 – Overviewing mechanistic function of SAAmplify-aSYN biomarker test, its purpose, and how it came about 7:50 – Results from the published study; ways the fluorescence-based amplification method could distinguish MSA from PD and Lewy body dementia 16:25 – Neurology News Minute 18:30 – Therapeutic feasibility of the assay in clinical settings and the next steps in validation The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: Axsome to Submit NDA for AXS-05 in Alzheimer Agitation Following Positive Phase 3 Trials FDA Clears IND for Trial Assessing Gene Therapy SGT-212 in Friedreich Ataxia FDA Grants Fast Track Designation to Anti-Tau Therapy Posdinemab Thanks for listening to the NeurologyLive ® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com .…
N
NeurologyLive® Mind Moments®

1 131: Neurology Unwrapped: 2024’s Most Intriguing Conversations 25:47
25:47
التشغيل لاحقا
التشغيل لاحقا
قوائم
إعجاب
احب25:47
Welcome to the NeurologyLive ® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this special episode, we’ve compiled some of the most compelling conversations from Mind Moments podcast episodes throughout 2024. These discussions spotlight groundbreaking research and advancements in neurology that are propelling the field forward. The NeurologyLive team also explored the impact of several newly FDA-approved therapies, offering clinicians valuable insights into what these treatments mean for patient care and their practical use in the clinic. Featured in this week’s episode, in order of appearance, are: Daniel Ontaneda, MD, PhD , a staff member of the Cleveland Clinic Mellen Center for Multiple Sclerosis, who gave an overview on the new 2024 McDonald criteria to diagnose multiple sclerosis (MS), which was presented at the 40th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) . Check out the full episode here: https://www.neurologylive.com/view/episode-125-understanding-major-changes-new-mcdonald-criteria-multiple-sclerosis Ian Kremer , executive director of the leaders Engaged on Alzheimer's Disease (LEAD) coalition, on the changing and exciting advances in Alzheimer disease therapeutics, as well as the discontinuation of aducanumab, the first approved antiamyloid therapy. Check out the full episode here: https://www.neurologylive.com/view/episode-113-lessons-learned-alzheimer-drug-development Andy Berkowski, MD, PhD , vice chair of the American Academy of Sleep Medicine's Practice Guidelines Task Force, discusses the newly revised guidelines for restless legs syndrome, including the latest updates in literature and changes to clinical care. Check out the full episode here: https://www.neurologylive.com/view/episode-129-implications-2024-aasm-guidelines-restless-legs-syndrome Sameea Husain-Wilson, DO , a movement disorder specialist at the Marcus Neuroscience Institute of Baptist Health, provided clinical perspective on the use of the Syn-One diagnostic test for patients with Parkinson disease. Check out the full episode here: https://www.neurologylive.com/view/episode-119-utilizing-the-syn-one-test-to-diagnose-parkinson-disease Jonathan Parker, MD, PhD , an assistant professor of neurosurgery at Mayo Clinic Arizona, spoke at the 2024 American Epilepsy Society Annual Meeting on cell therapy approaches for epilepsy, the challenges the clinical community faces, and the outlook for the future. Check out the full episode here: https://www.neurologylive.com/view/episode-130-promise-behind-cell-therapy-approaches-epilepsy Lawrence Robinson, MD , a senior scientist at Sunnybrook Research Institute, gives insight on educating the next generation of neuromuscular and electrodiagnostic (EDX) practitioners, and the major differences in how this generation of medical students learn relative to previous ones. Check out the full episode here: https://www.neurologylive.com/view/episode-127-adapting-neuromuscular-electrodiagnostic-medicine-education-modern-learners Want more Mind Moments episodes? Click here for all of NeurologyLive®'s podcast episodes . Episode Breakdown: 1:05 – Ontaneda on the incorporation of new biomarkers into the 2024 McDonald Criteria for multiple sclerosis. 7:35 – Kremer on the lessons learned from drug development, including antiamyloid treatments, and initial reaction to the discontinuation of aducanumab for AD. 10:30 – Berkowski on the outlook of treating and preventing restless legs syndrome going forward using the newly updated American Academy of Sleep Medicine treatment guidelines. 13:10 – Husain-Wilson on the function of the Syn-One test for Parkinson disease, its applicability, and how it may distinguish patients with PD from other synucleinopathies. 18:40 – Parker on the promise and thought process behind stem cell approaches for drug-resistant epilepsy, including the different types of cell methods being tested. 21:45 – Robinson on the distinct differences in learning styles based on generation, the importance of adaptive teaching, and the new approaches educators in neuromuscular and electrodiagnostic medicine can take. Thanks for listening to the NeurologyLive ® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com .…
N
NeurologyLive® Mind Moments®

1 130: The Promise Behind Cell Therapy Approaches in Epilepsy 23:36
23:36
التشغيل لاحقا
التشغيل لاحقا
قوائم
إعجاب
احب23:36
Welcome to the NeurologyLive ® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, Jonathan Parker, MD, PhD, an assistant professor of neurosurgery at Mayo Clinic Arizona, spoke about the emerging commotion around cell therapies as a way to treat patients with epilepsy. The discussion, which took place at the 2024 American Epilepsy Society (AES) Annual Meeting in Los Angeles, California, covers the thought process behind this approach and why it may hold greater advantages over other traditional surgeries that result in detrimental cognitive effects. Parker, director of the Device-Based Neuroelectronics Lab, spoke on the different types of cell therapies currently in development, the limitations and challenges associated with these medications, and the need to create innovative trials to appropriately test them. Furthermore, Parker spoke on the therapeutic pipeline of cell therapies for epilepsy, including his experience leading a study site for a first-in-human trial of an investigational agent NRTX-1001, a product derived from human pluripotent stem cells. Looking for more epilepsy discussion? Check out the NeurologyLive ® Epilepsy clinical focus page . Episode Breakdown: 1:00 – Idea behind cell therapy to treat epilepsy 4:05 – Current state of stem cell therapies for neurological disorders, focusing on Parkinson disease, stroke, and epilepsy 8:05 – NTE001 study of NRTX-1001, an investigational human embryonic stem cell product 11:45 – Neurology News Minute 13:50 – Unanswered questions and safety concerns with cell therapies; challenges with clinical trial design and the need for more innovative trials 17:35 – Misconceptions or gaps in understanding about cell therapies for epilepsy 20:05 – Unique challenges and potential of stem cell therapies for epilepsy, particularly in younger patients; patient motivation and hope The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: Anavex Submits Marketing Authorization Application for Blarcamesine in Alzheimer Disease in the EU Testing Begins for RELIEV-CM2 Study of ShiraTronics Neuromodulation Device in Chronic Migraine STK-001 Gains FDA Breakthrough Designation as Potential Disease-Modifying Treatment for Dravet Syndrome Thanks for listening to the NeurologyLive ® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com .…
N
NeurologyLive® Mind Moments®

1 129: Implications of the 2024 AASM Guidelines for Restless Legs Syndrome 24:25
24:25
التشغيل لاحقا
التشغيل لاحقا
قوائم
إعجاب
احب24:25
Welcome to the NeurologyLive ® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, Andy Berkowski, MD, PhD, founder of Relax Health, sat down to discuss the American Academy of Sleep Medicine's (AASM) recently published guideline update for the treatment of restless legs syndrome (RLS). Berkowski, who serves as a vice chair of the AASM's Practice Guidelines Task Force, provided clinical insight on the reasons behind the guidelines, pointing to the vast research advances and literature updates since its last iteration in 2012. Additionally, he touched on the greatest changes to the guidelines, noting things like the shift away from dopaminergic agents, the importance of iron in RLS pathophysiology, and the use of alpha-2-delta ligands and intravenous iron as first-line treatments. Berkowski also shared thoughts on how the guidelines impact care for patients of all ages, sexes, and RLS subtypes, as well as some of the more troubling parts of the guidelines to write and areas that were left unanswered. Furthermore, he gave his thoughts on how these guidelines will transform care going forward, including accelerating conversations on preventing RLS in many cases in the near future. Looking for more sleep disorder discussion? Check out the NeurologyLive ® Sleep disorders clinical focus page . Episode Breakdown: 1:00 – Reasons behind new guidelines, progress in clinical research 2:50 – Overview of the greatest changes to the guidelines and what treating physicians should key in on 11:25 – Neurology News Minute 13:40 – How the guidelines address management based on age, sex, and RLS subtype 16:30 – Challenges when drafting the guidelines and the unanswered questions that remain 20:10 – A promising future for treating, managing, and preventing RLS The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: Neurogene Reports Serious Adverse Event in Phase 1/2 Rett Study of Gene Therapy NGN-401 Huntington Agent SAGE-718 to be Discontinued Following Disappointing Phase 2 DIMENSION Trial Results Alzheimer Agent Simufilam Fails to Meet Primary End Point in Phase 3 Study Thanks for listening to the NeurologyLive ® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com .…
N
NeurologyLive® Mind Moments®

1 128: Machine Learning Algorithms to Predict Seizure Control in Epilepsy Surgery 21:12
21:12
التشغيل لاحقا
التشغيل لاحقا
قوائم
إعجاب
احب21:12
Welcome to the NeurologyLive ® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, Lara Jehi, MD, MHCDS, an epilepsy specialist and Cleveland Clinic’s Chief Research and Information Officer, sat down to discuss a recently published study that explored using machine learning algorithms to predict seizure control after epilepsy surgery. In the interview, Jehi explained the unique aspects of the study design, emphasizing the importance of a large, well-characterized patient cohort with consistent follow-up and the choice of scalp EEG—a commonly used, non-invasive test in epilepsy care—as the data source. In addition, Jehi touched on the use of AutoML to streamline the process, enabling efficient identification of the top-performing algorithms and enhancing the model’s predictive accuracy. Furthermore, she spoke on the team needed to properly implement machine learning techniques for neurosurgery, while providing recommendations for other institutions interested in pursuing these types of approaches. Looking for more epilepsy discussion? Check out the NeurologyLive ® epilepsy clinical focus page . Episode Breakdown: 1:00 – Background on various machine learning approaches for epilepsy research 3:20 – Study details, findings, and notable takeaways 8:20 – Neurology News Minute 10:20 – Novelty in using scalp EEG and its global application 15:30 – Team personnel needed for proper implementation of machine learning techniques in epilepsy surgery The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: FDA Accepts Resubmitted NDA for Ataluren in Nonsense Duchenne Muscular Dystrophy FDA Places Clinical Hold on Epilepsy Agent RAP-219 for Diabetic Peripheral Neuropathic Pain First-Ever CRISPR/Cas13-RNA Editing Therapy to be Tested in Phase 1 Study of Age-Related Macular Degeneration Thanks for listening to the NeurologyLive ® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com .…
N
NeurologyLive® Mind Moments®

1 127: Adapting Neuromuscular and Electrodiagnostic Medicine Education for Modern Learners 15:03
15:03
التشغيل لاحقا
التشغيل لاحقا
قوائم
إعجاب
احب15:03
Welcome to the NeurologyLive ® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, Lawrence Robinson, MD, a senior scientist at Sunnybrook Research Institute, sat down to discuss his presentation from the 2024 American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) annual meeting, focused on educating the next generation of neuromuscular and electrodiagnostic (EDX) practitioners. Robinson gave an overview of his presentation, why this was a topic of interest, and the major differences in how this generation of medical students learn relative to previous ones. In addition, he discussed adapting to new learning styles, the benefits of flipped classrooms, and the impact of technology on education and practice. Furthermore, he touched upon the personal connections and humor in teaching, as well as ways to improve critical evaluation skills as a learner. Looking for more neuromuscular discussion? Check out the NeurologyLive ® neuromuscular clinical focus page . Episode Breakdown: 1:05 – Overviewing and background on AANEM presentation 3:15 – Challenges with educating next generation of neuromuscular and EDX practitioners 4:40 – Areas of opportunity and growth for these next generation learners 5:50 – Neurology News Minute 8:00 – Novelty and advantages of flipped classroom approaches to teaching 10:10 – Future expected changes to neuromuscular care 11:55 – Final thoughts on care on NM and EDX education The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: Phase 3 ENSURE Program of Vidofludimus Calcium Continues Following Positive Futility Analysis Gene Therapy FLT201 Shows Promise in Early-Stage Study of Gaucher Disease Risk of ARIA-E in Donanemab Attenuated Through New Enhanced Titration Method of Delivery Thanks for listening to the NeurologyLive ® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com .…
N
NeurologyLive® Mind Moments®

1 Special Episode: FDA Approves Sodium Oxybate for Pediatric Narcolepsy 12:23
12:23
التشغيل لاحقا
التشغيل لاحقا
قوائم
إعجاب
احب12:23
Welcome to this special episode of the NeurologyLive ® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. For major FDA decisions in the field of neurology, we release short special episodes to offer a snapshot of the news, including the main takeaways for the clinical community, as well as highlights of the efficacy and safety profile of the agent in question. In this episode, we cover the recent approval of Avadel's sodium oxybate formulation (Lumryz) as a treatment for pediatric patients with narcolepsy aged 7 years and older. The new indication expands on its previous one, granted in May 2023, which included the the treatment of cataplexy or excessive daytime sleepiness in adults with narcolepsy. It's initial approval was based on data from the phase 3 REST-ON trial (NCT02720744), a large-scale study in which the therapy met all 3 of its primary end points of change from baseline in mean sleep latency on the Maintenance of Wakefulness test, Clinical Global Impression Improvement, and weekly cataplexy attacks. Following its new indication, NeurologyLive sat down with Anne Marie Morse, DO, FAASM, a pediatric sleep disorders expert, to discuss the significance of the new approval. Morse, director of Child Neurology and Pediatric Sleep Medicine at Geisinger Janet Weis Children's Hospital as well as the program director for Child Neurology Residency Program, provided commentary on the clinical considerations behind this once-nightly formulation of sodium oxybate, and how it should be used going forward. For more of NeurologyLive 's coverage of sodium oxybate's (Lumryz) expanded indication, head here: FDA Approves Avadel's Sodium Oxybate for Cataplexy or Excessive Daytime Sleepiness in Pedatric Narcolepsy Episode Breakdown: 2:10 – Immediate reaction and significance 4:10 – Considerations and caution with prescribing sodium oxybate 8:20 – Closing remarks and the need to utilize highly effective treatments for narcolepsy Thanks for listening to the NeurologyLive Mind Moments podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com .…
N
NeurologyLive® Mind Moments®

1 126: Therapeutic Potential of ATH434 in Multiple System Atrophy 14:24
14:24
التشغيل لاحقا
التشغيل لاحقا
قوائم
إعجاب
احب14:24
Welcome to the NeurologyLive ® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, Daniel Claaseen, MD, MS, a professor of neurology and chief of the Behavioral and Cognitive Neurology Division at Vanderbilt University Medical Center, offered his insight on phase 1/2 data that was recently presented at the International Parkinson and Movement Disorder Society (MDS) Congress on ATH434, an investigational drug in development from Alterity Therapeutics for multiple system atrophy (MSA). He dove into the therapy's mechanism of action and the currently known safety profile and considerations for its use, as well as the next steps in advancing care for patients with MSA as a whole. Looking for more movement disorders discussion? Check out the NeurologyLive ® movement disorder clinical focus page . Episode Breakdown: 1:10 – Overviewing the conduct of the phase 1/2 studies 3:00 – Notable findings from data presented at MDS 4:30 – Mechanism of action behind ATH434 8:20 – Neurology News Minute 10:20 – Next steps in ATH434's development 11:15 – Current unmet needs for patients with MSA The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: FDA Removes Partial Hold for Myotonic Dystrophy Agent AOC 1001 FDA Approves Avadel's Sodium Oxybate for Cataplexy or Excessive Daytime Sleepiness in Pedatric Narcolepsy FDA Approves AbbVie’s 24-Hour Foscarbidopa/Foslevodopa Pump for Advanced Parkinson Disease Treatment Thanks for listening to the NeurologyLive ® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com .…
N
NeurologyLive® Mind Moments®

1 125: Understanding Major Changes to New McDonald Criteria for Multiple Sclerosis 27:02
27:02
التشغيل لاحقا
التشغيل لاحقا
قوائم
إعجاب
احب27:02
Welcome to the NeurologyLive ® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, Daniel Ontaneda, MD, PhD, a staff member of the Cleveland Clinic Mellen Center for Multiple Sclerosis, provided an in-depth overview on the newly announced McDonald criteria to diagnose multiple sclerosis (MS). Ontaneda, who also serves as an assistant professor of neurology, discussed the most notable changes to the criteria and how it may help towards improving rates of misdiagnosis and missed diagnosis. He spoke on the incorporation of new biomarkers, such as central vein sign and paramagnetic rim lesions, and the ability to diagnose MS in stages before clinical presentation shows. Furthermore, Ontaneda gave some perspective on the areas of the new criteria that will take some time to adjust to, as well as how these criteria may change the philosophical perspective of the disease as a whole. Looking for more Multiple sclerosis discussion? Check out the NeurologyLive ® multiple sclerosis clinical focus page . Episode Breakdown: 1:10 – Focus and direction of new diagnostic criteria 3:00 – Overviewing specific changes to McDonald criteria 10:50 – Approach to diagnosing pre-MS; treating radiologically isolated syndrome earlier 12:55 – Neurology News Minute 15:10 – Incorporation of new biomarkers, central vein sign, paramagnetic rim lesions, OCT 21:45 – Unanswered questions/challenges left out of the diagnostic criteria The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: Potential Regulatory Submission for Inebilizumab in Myasthenia Gravis Following Positive Phase 3 MINT Data Parkinson Agent Tavapadon Meets Primary and Secondary End Points as Monotherapy in Phase 3 TEMPO-1 Trial Sage Therapeutics and Biogen Officially Announce Ending of SAGE-324 Program in Essential Tremor Thanks for listening to the NeurologyLive ® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com .…
N
NeurologyLive® Mind Moments®

1 124: Therapeutic Updates and Progress in Treating Becker Muscular Dystrophy 19:45
19:45
التشغيل لاحقا
التشغيل لاحقا
قوائم
إعجاب
احب19:45
Welcome to the NeurologyLive ® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, Joanne Donovan, MD, PhD, chief medical officer at Edgewise Therapeutics, sat down to discuss the clinical program of EDG-5506, an investigational drug in development for Becker muscular dystrophy, and the recent progress in treating and understanding Becker muscular dystrophy. She spoke on the mechanism of action of the drug, also known as sevasemten, and why the company believes it can be therapeutically beneficial for this patient population. Furthermore, Donovan spoke on the previous failures in drug development for Becker, advances in biomarker detection, and how other trials paved the way for the company's phase 2 study and open label extension, dubbed CANYON (NCT05291091) and GRAND CANYON. Furthermore, she spoke on the ways the clinical community has tried to improve the quality of life for patients with Becker, focusing on approaches and tactics that curve cardiac issues commonly seen in this group. Looking for more Neuromuscular discussion? Check out the NeurologyLive ® neuromuscular clinical focus page . Episode Breakdown: 1:15 – Overview of CANYON study and extension phase 3:50 – Mechanism of action of EDG-5506 6:30 – How previous trial experiences shaped CANYON 10:10 – Neurology News Minute 11:50 – Ongoing challenges with treating and testing drugs for Becker 15:25 – Safety profile of EDG-5506 16:45 – Ways to tackle cardiac issues in Becker The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: Digital Therapeutic CT-132 Meets Primary End Point in Phase 3 Study of Preventive Migraine FDA Supports Alpha-Synuclein Seed Amplification Assay Biomarker for Clinical Trials in Parkinson Disease FDA Approves Subcutaneous Formulation of Ocrelizumab for Relapsing and Progressive Multiple Sclerosis Thanks for listening to the NeurologyLive ® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com .…
N
NeurologyLive® Mind Moments®

1 123: Previewing Cleveland Clinic's Epilepsy Summit 22:54
22:54
التشغيل لاحقا
التشغيل لاحقا
قوائم
إعجاب
احب22:54
Welcome to the NeurologyLive ® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, epilepsy expert Imad Najm, MD, PhD, sat down to discuss the upcoming Cleveland Clinic Epilepsy Summit, an educational symposium that takes place September 11-15, in Cleveland, Ohio. Najm, who serves as the director of Cleveland Clinic's Epilepsy Center at the Cleveland Clinic Neurological Institute, spoke about the objectives and goals of the meeting, including updates on sEEG, epilepsy surgery, treatments for drug-resistant epilepsy, and gene therapy. In addition, he provided an overview of the latest advances in epilepsy surgery, genetics, and seizure controlling approaches. Furthermore, he spoke on some of the educational challenges with adjusting to changes in neurosurgery, the potential benefits and limitations of gene therapy, and the future of epilepsy treatment. Looking for more Epilepsy discussion? Check out the NeurologyLive ® Epilepsy clinical focus page . Episode Breakdown: 1:10 – Mission and goals of Epilepsy Summit 3:05 – Overviewing sessions and educational attainment 4:55 – Changes to epilepsy surgery, advances over the years 9:15 – Neurology News Minute 11:50 – Learning curve for understanding new epilepsy surgery tactics 13:50 – Closing thoughts on the upcoming meeting 15:50 – Potential benefits and challenges to gene therapy for epilepsy The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: EMA Accepts Marketing Authorization Application for Huntington Disease Agent Pridopidine BTK Inhibitor Tolebrutinib Slows Disability Progression in Phase 3 HERCULES Study of Non-Relapsing Secondary Progressive MS FDA Accepts Resubmitted New Drug Application for Migraine Treatment AXS-07 Thanks for listening to the NeurologyLive ® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com .…
N
NeurologyLive® Mind Moments®

1 122: RNA Therapeutics, Mivelsiran, and Treating Alzheimer Disease 24:29
24:29
التشغيل لاحقا
التشغيل لاحقا
قوائم
إعجاب
احب24:29
Welcome to the NeurologyLive ® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, Sharon Cohen, MD, a behavioral neurologist, sat down to discuss positive data from an ongoing phase 1 study of mivelsiran (Alnylam Pharmaceuticals), the first investigational RNA interference therapeutic targeting amyloid precursor protein for Alzheimer disease (AD). Cohen, who also serves as the medical director of the Toronto Memory Program at the University of Toronto, discussed the potential of RNA therapeutics for treating AD, the unique mechanism of action of mivelsiran, and some of the early promising safety, efficacy, and pharmacokinetic data observed in the phase 1 trial. In addition, Cohen touched upon the idea of how RNA therapeutics could be used in combination with previously approved novel treatments and the benefits mivelsiran brings with no observed amyloid-related imaging abnormalities. Furthermore, the discussion covered some of the potential of this investigational agent, what to expect in the multi-dose part B of the study, and an additional phase 2 study in cerebral amyloid angiopathy. Looking for more Alzheimer disease/dementia discussion? Check out the NeurologyLive ® Alzheimer disease/dementia clinical focus page . Episode Breakdown: 1:15 – Mechanism of action of mivelsiran and how it can be potentially beneficial in AD 4:15 – Growing knowledge of RNA therapeutics and their impact on neurologic conditions 7:00 – Neurology News Minute 10:10 – Phase 1 study data, including efficacy, safety, biomarker, and pharmacokinetic results 19:20 – How mivelsiran fits with other approved therapies for AD; future goals and directions of the drug The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: FDA Clears Indapta Therapeutics’ IND for Cell Therapy IDP-023 in Progressive Multiple Sclerosis Muscle-Targeting Therapy Apitegromab Effective in Spinal Muscular Atrophy Over 4 Year Period FDA Approves Medtronic’s Deep Brain Stimulation Technology for Asleep Capabilities Thanks for listening to the NeurologyLive ® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com .…
مرحبًا بك في مشغل أف ام!
يقوم برنامج مشغل أف أم بمسح الويب للحصول على بودكاست عالية الجودة لتستمتع بها الآن. إنه أفضل تطبيق بودكاست ويعمل على أجهزة اندرويد والأيفون والويب. قم بالتسجيل لمزامنة الاشتراكات عبر الأجهزة.